Tien Liang BioTech Past Earnings Performance
Past criteria checks 2/6
Tien Liang BioTech has been growing earnings at an average annual rate of 62.2%, while the Pharmaceuticals industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 2% per year. Tien Liang BioTech's return on equity is 3.6%, and it has net margins of 3.9%.
Key information
62.2%
Earnings growth rate
62.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 2.0% |
| Return on equity | 3.6% |
| Net Margin | 3.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Tien Liang BioTech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 460 | 18 | 266 | 1 |
| 30 Sep 23 | 477 | 26 | 268 | 1 |
| 30 Jun 23 | 490 | 36 | 272 | 1 |
| 31 Mar 23 | 504 | 41 | 276 | 1 |
| 31 Dec 22 | 529 | 59 | 277 | 1 |
| 30 Sep 22 | 558 | 70 | 280 | 1 |
| 30 Jun 22 | 595 | 82 | 285 | 1 |
| 31 Mar 22 | 608 | 83 | 287 | 1 |
| 31 Dec 21 | 571 | 47 | 294 | 1 |
| 30 Sep 21 | 518 | 7 | 298 | 1 |
| 30 Jun 21 | 455 | -32 | 300 | 1 |
| 31 Mar 21 | 423 | -62 | 305 | 1 |
| 31 Dec 20 | 431 | -52 | 301 | 1 |
| 30 Sep 20 | 452 | -26 | 291 | 1 |
| 30 Jun 20 | 450 | -33 | 290 | 1 |
| 31 Mar 20 | 446 | -31 | 292 | 1 |
| 31 Dec 19 | 436 | -47 | 301 | 1 |
| 30 Sep 19 | 452 | -90 | 312 | 1 |
| 30 Jun 19 | 478 | -101 | 323 | 2 |
| 31 Mar 19 | 520 | -103 | 338 | 3 |
| 31 Dec 18 | 534 | -94 | 344 | 3 |
| 30 Sep 18 | 518 | -66 | 362 | 3 |
| 30 Jun 18 | 494 | 37 | 389 | 2 |
| 31 Mar 18 | 472 | -196 | 412 | 2 |
| 31 Dec 17 | 515 | -203 | 451 | 2 |
| 30 Sep 17 | 563 | -230 | 473 | 1 |
| 30 Jun 17 | 641 | -317 | 488 | 1 |
| 31 Mar 17 | 716 | -75 | 489 | 2 |
| 31 Dec 16 | 756 | -53 | 481 | 2 |
| 30 Sep 16 | 765 | -27 | 474 | 2 |
| 30 Jun 16 | 788 | -1 | 460 | 3 |
| 31 Mar 16 | 813 | 24 | 462 | 2 |
| 31 Dec 15 | 841 | 49 | 460 | 2 |
| 30 Sep 15 | 863 | 67 | 469 | -8 |
| 30 Jun 15 | 886 | 76 | 461 | -5 |
| 31 Mar 15 | 875 | 74 | 444 | -2 |
| 31 Dec 14 | 844 | 61 | 428 | 1 |
| 30 Sep 14 | 826 | 52 | 405 | 13 |
| 30 Jun 14 | 794 | 45 | 394 | 14 |
| 31 Mar 14 | 855 | 53 | 420 | 14 |
| 31 Dec 13 | 918 | 49 | 453 | 15 |
| 30 Sep 13 | 978 | 50 | 472 | 17 |
| 30 Jun 13 | 1,001 | 40 | 485 | 17 |
Quality Earnings: 4127 has high quality earnings.
Growing Profit Margin: 4127's current net profit margins (3.9%) are lower than last year (11.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4127 has become profitable over the past 5 years, growing earnings by 62.2% per year.
Accelerating Growth: 4127's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 4127 had negative earnings growth (-70.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-15%).
Return on Equity
High ROE: 4127's Return on Equity (3.6%) is considered low.